Suppression of CXCL-1 Could Restore Necroptotic Pathway in Chronic Lymphocytic Leukemia

Overview

Journal Onco Targets Ther

Publisher Dove Medical Press

Specialty Oncology

Date 2020 Aug 9

PMID 32764983

Citations 4

Authors

Zhao Xu

Yifeng Sun

Zheng Wei

Jifeng Jiang

Jiadai Xu

Peng Liu

Affiliations

Soon will be listed here.

Abstract

Purpose: To clarify the role of different cytokines and selenite in the defective necroptotic pathway of chronic lymphocytic leukemia (CLL).

Patients And Methods: We randomly collected the peripheral blood samples of 11 untreated CLL patients and 10 healthy volunteers, and then separated B lymphocytes from peripheral blood. Then, real-time polymerase chain reaction (PCR), enzyme-linked immunosorbent assay (ELISA) and Western Blot were performed to detect the expression of different cytokines, including CXC-motif chemokine ligand 1 (CXCL-1). Finally, we used flow cytometry to analyze the percentage of surviving cells to figure out whether CLL cells or normal B lymphocytes underwent necroptosis.

Results: 1) The high expression of CXCL-1 was seen in CLL cells compared with normal B lymphocytes (p = 0.0001, adjusted p =0.0012); 2) The downregulation of CXCL-1 was shown in normal B lymphocytes after induction by TNF-α and z-VAD; 3) CLL cells could restore necroptosis induced by TNF-α and z-VAD after knockdown of CXCL-1; 4) The transcriptional and translational expression of LEF-1 were downregulated after the knockdown of CXCL-1 in CLL cells; 5. 3.2μM selenite could help CLL cells restore necroptosis (p = 0.0102) and inhibit the transcriptional and translational expression of CXCL-1.

Conclusion: CXCL-1 played an important role in the defective necroptosis of CLL cells and regulated the expression of LEF-1. Selenite could inhibit the expression of CXCL-1 and help CLL cells restore necroptosis together with TNF-α and z-VAD. Selenite might be the potential medication of CLL in the future.

Citing Articles

Deregulation of New Cell Death Mechanisms in Leukemia.

Favale G, Donnarumma F, Capone V, Della Torre L, Beato A, Carannante D Cancers (Basel). 2024; 16(9).

PMID: 38730609 PMC: 11083363. DOI: 10.3390/cancers16091657.

Bioinformatics Analysis of Prognostic Significance and Immune Characteristics of CXC Chemokine Family in Patients with Lung Adenocarcinoma.

Bian D, Chen Y Comput Math Methods Med. 2022; 2022:3918926.

PMID: 35844446 PMC: 9279080. DOI: 10.1155/2022/3918926.

Arhgap21 Deficiency Results in Increase of Osteoblastic Lineage Cells in the Murine Bone Marrow Microenvironment.

Pissarra M, Torello C, Gomes R, Shiraishi R, Santos I, Vieira Ferro K Front Cell Dev Biol. 2021; 9:718560.

PMID: 34917608 PMC: 8670086. DOI: 10.3389/fcell.2021.718560.

Anticoagulants Used in Cardiac Catheterization of Patients With Chronic Lymphocytic Leukemia: A Case Report and Overview.

Mararenko A, Alshami A, AlAzzawi M, Patel S Cureus. 2021; 13(3):e13633.

PMID: 33816032 PMC: 8011627. DOI: 10.7759/cureus.13633.

References

Tsukamoto H, Nishikata R, Senju S, Nishimura Y . Myeloid-derived suppressor cells attenuate TH1 development through IL-6 production to promote tumor progression. Cancer Immunol Res. 2014; 1(1):64-76. DOI: 10.1158/2326-6066.CIR-13-0030. View

Tsukamoto H, Senju S, Matsumura K, Swain S, Nishimura Y . IL-6-mediated environmental conditioning of defective Th1 differentiation dampens antitumour immune responses in old age. Nat Commun. 2015; 6:6702. PMC: 4396369. DOI: 10.1038/ncomms7702. View

Ha H, Debnath B, Neamati N . Role of the CXCL8-CXCR1/2 Axis in Cancer and Inflammatory Diseases. Theranostics. 2017; 7(6):1543-1588. PMC: 5436513. DOI: 10.7150/thno.15625. View

Kogan-Sakin I, Cohen M, Paland N, Madar S, Solomon H, Molchadsky A . Prostate stromal cells produce CXCL-1, CXCL-2, CXCL-3 and IL-8 in response to epithelia-secreted IL-1. Carcinogenesis. 2009; 30(4):698-705. DOI: 10.1093/carcin/bgp043. View

Bjorkhem-Bergman L, Jonsson K, Eriksson L, Olsson J, Lehmann S, Paul C . Drug-resistant human lung cancer cells are more sensitive to selenium cytotoxicity. Effects on thioredoxin reductase and glutathione reductase. Biochem Pharmacol. 2002; 63(10):1875-84. DOI: 10.1016/s0006-2952(02)00981-4. View

Obermueller E, Vosseler S, Fusenig N, Mueller M . Cooperative autocrine and paracrine functions of granulocyte colony-stimulating factor and granulocyte-macrophage colony-stimulating factor in the progression of skin carcinoma cells. Cancer Res. 2004; 64(21):7801-12. DOI: 10.1158/0008-5472.CAN-03-3301. View

Kurtova A, Balakrishnan K, Chen R, Ding W, Schnabl S, Quiroga M . Diverse marrow stromal cells protect CLL cells from spontaneous and drug-induced apoptosis: development of a reliable and reproducible system to assess stromal cell adhesion-mediated drug resistance. Blood. 2009; 114(20):4441-50. PMC: 4081374. DOI: 10.1182/blood-2009-07-233718. View

Dhawan P, Richmond A . Role of CXCL1 in tumorigenesis of melanoma. J Leukoc Biol. 2002; 72(1):9-18. PMC: 2668262. View

Zhou L, Jiang Y, Liu X, Li L, Yang X, Dong C . Promotion of tumor-associated macrophages infiltration by elevated neddylation pathway via NF-κB-CCL2 signaling in lung cancer. Oncogene. 2019; 38(29):5792-5804. DOI: 10.1038/s41388-019-0840-4. View

10.

Vandenabeele P, Vanden Berghe T, Festjens N . Caspase inhibitors promote alternative cell death pathways. Sci STKE. 2006; 2006(358):pe44. DOI: 10.1126/stke.3582006pe44. View

11.

Akram I, Georges R, Hielscher T, Adwan H, Berger M . The chemokines CCR1 and CCRL2 have a role in colorectal cancer liver metastasis. Tumour Biol. 2015; 37(2):2461-71. DOI: 10.1007/s13277-015-4089-4. View

12.

Wallenberg M, Misra S, Wasik A, Marzano C, Bjornstedt M, Gandin V . Selenium induces a multi-targeted cell death process in addition to ROS formation. J Cell Mol Med. 2014; 18(4):671-84. PMC: 4000118. DOI: 10.1111/jcmm.12214. View

13.

Sonkusre P, Cameotra S . Biogenic selenium nanoparticles induce ROS-mediated necroptosis in PC-3 cancer cells through TNF activation. J Nanobiotechnology. 2017; 15(1):43. PMC: 5463494. DOI: 10.1186/s12951-017-0276-3. View

14.

Gutschalk C, Herold-Mende C, Fusenig N, Mueller M . Granulocyte colony-stimulating factor and granulocyte-macrophage colony-stimulating factor promote malignant growth of cells from head and neck squamous cell carcinomas in vivo. Cancer Res. 2006; 66(16):8026-36. DOI: 10.1158/0008-5472.CAN-06-0158. View

15.

. IL15 is linked to antitumor immune responses in colorectal cancer. Cancer Discov. 2014; 4(5):OF9. DOI: 10.1158/2159-8290.CD-RW2014-077. View

16.

Abangan Jr R, Williams C, Mehrotra M, Duncan J, LaRue A . MCP1 directs trafficking of hematopoietic stem cell-derived fibroblast precursors in solid tumor. Am J Pathol. 2010; 176(4):1914-26. PMC: 2843480. DOI: 10.2353/ajpath.2010.080839. View

17.

Shanafelt T, Wang X, Kay N, Hanson C, OBrien S, Barrientos J . Ibrutinib-Rituximab or Chemoimmunotherapy for Chronic Lymphocytic Leukemia. N Engl J Med. 2019; 381(5):432-443. PMC: 6908306. DOI: 10.1056/NEJMoa1817073. View

18.

Mueller M, Riede D, Lange M, Steiner H, Fusenig N . Autocrine growth regulation by granulocyte colony-stimulating factor and granulocyte macrophage colony-stimulating factor in human gliomas with tumor progression. Am J Pathol. 1999; 155(5):1557-67. PMC: 1866994. DOI: 10.1016/S0002-9440(10)65472-7. View

19.

Gruszka A, Valli D, Alcalay M . Wnt Signalling in Acute Myeloid Leukaemia. Cells. 2019; 8(11). PMC: 6912424. DOI: 10.3390/cells8111403. View

20.

Tulotta C, Lefley D, Freeman K, Gregory W, Hanby A, Heath P . Endogenous Production of IL1B by Breast Cancer Cells Drives Metastasis and Colonization of the Bone Microenvironment. Clin Cancer Res. 2019; 25(9):2769-2782. DOI: 10.1158/1078-0432.CCR-18-2202. View